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Abstract
Background:  Diabetics with erectile dysfunction have a high prevalence of microvascular
disturbance of the coronary circuit as measured by coronary flow reserve (CFR).
Purpose: We aimed to evaluate the effects of the phosphodiesterase 5 inhibitor sildenafil on CFR
in diabetics with erectile dysfunction.
Methods:  Diabetics seeking diabetes refinement therapy were screened for vascular or
neurogenic erectile dysfunction which was confirmed in 43 patients. No ischemic ECG changes
were found in any of the ECG stress tests at the 100 W level. Cardiologic examinations raised
suspicion of coronary artery disease in 16 patients; coronary angiography confirmed severe
coronary artery lesions in 12, who were excluded from further analysis. CFR measurements were
not possible in 10 participants. The 21 diabetics eligible for CFR measurements aged 60 years (50–
69) had known diabetes for 11 years (3–30) and a BMI of 27 kg/m2 (24–36). CFR of the left anterior
descending artery was assessed at baseline and 1 hour after 50 mg sildenafil, using transthoracic
Doppler echocardiography.
Results: Baseline CFR was at the lower level of the normal range (median 245%, range 210 –
490%). After sildenafil administration, CFR decreased insignificantly (∆CFR -10%, p = 0.3). Patients
with a BMI > 25 kg/m2 and left ventricular hypertrophy exhibited the highest reduction of CFR after
sildenafil. No decrease of CFR below 200 % was observed. Systemic blood pressure dropped from
130/80 mmHg to 120/72 mmHg (p < 0.002).
Conclusions:  Diabetics with erectile dysfunction exhibit a CFR in the lower normal range
indicating severe microvascular disturbance. Sildenafil did not alter CFR in those patients. A high
prevalence of severe coronary macroangiopathy was identified in asymptomatic diabetic patients
screened for contraindications for sildenafil.
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Introduction
Diabetic patients have a high prevalence of erectile dys-
function which is mainly caused by disturbance of the
microvascular bed [1,2]. This disturbance can be
enhanced by hypertension, hyperlipoproteinemia and
smoking, which are also risk factors for macroangiopathy
[3,4]. Therefore diabetics with erectile dysfunction and
the presence of other cardiovascular risk factors have a
higher likelihood of having coronary artery disease [5,6].
Symptoms are often absent in those patients despite
severe myocardial ischemia.
In earlier investigations it was demonstrated that the ade-
nosine-mediated flow reserve (CFR) of the left anterior
descending (LAD) artery is reduced to values in the lower
normal range in most diabetic patients, indicating distur-
bance of microvascular flow dynamics [7]. Reduction of
CFR below a cut-off value of 200% is closely correlated
with exercise-induced myocardial ischemia by either
microvascular dysfunction or significant coronary artery
stenoses [8,9]. Our aim was to evaluate whether sildenafil
alters CFR in diabetics with erectile dysfunction.
Methods
Study Population
Diabetic males aged 25–75 years who reported erectile
dysfunction were eligible for the study. Patients who had
diabetes less than 1 year, psychogenic erectile dysfunc-
tion, history of a myocardial infarction or significant cor-
onary artery lesions, impaired systolic left ventricular
function, right or left bundle block, or atrial fibrillation
were not considered for the study. The study was
approved by a local ethical rights committee. All patients
gave written informed consent.
Study Protocol
Patients visiting our outpatient endocrinology depart-
ment for refinement of anti-diabetic therapy were
screened. Those suitable for enrollment were referred to
the urology department to confirm erectile dysfunction.
Patients were examined by color Doppler ultrasound of
the penile blood supply before and after intracavernous
injection of 10 µg PGE5. Only patients with vascular or
neurogenic erectile dysfunction were included. For cardiac
evaluation, patients were questioned by a cardiologist; an
ECG and a transthoracic echocardiography were also per-
formed. Left ventricular hypertrophy was determined to
be present if the thickness of the interventricular septum
was > 12 mm as assessed by echocardiography using the
parasternal long-axis view. Diastolic dysfunction of the
left ventricle was diagnosed if the ratio of the E and A
waves of the transmitral flow profile was inverted and if
the E wave deceleration time was > 250 ms, which was
associated with an isovolumetric relaxation time of > 100
ms. A stress ECG had to be performed at a work load of at
least 100 W or ≥ 5 METS. Patients with symptoms of
angina pectoris or ischemic ECG changes were excluded
from the study.
In patients with no contraindications, CFR baseline meas-
urements were performed. Therefore, patients received a
venous cannula and had to rest for 30 min in the supine
position. Then blood pressure was measured and CFR
measurement performed. Patients with a baseline CFR >
200% received 50 mg sildenafil (Viagra, Pfizer Inc., USA)
and after 30 minutes were asked to rest again in the supine
position for another 30 minutes. Repeat measurements of
blood pressure and CFR were performed thereafter.
Assessment of Coronary Flow Reserve
The technique of CFR assessment by transthoracic
echocardiography was described previously [10]. In brief,
to visualize the mid or distal portion of the left anterior
descending coronary artery (LAD) we used a 3.5 or 7 MHz
transducer (Siemens-Acuson, Sequoia, C 256). First, the
anterior groove was imaged in a modified parasternal
short-axis view. Using color Doppler the LAD can be
detected in the anterior groove area as a circularly shaped
color Doppler signal with predominantly diastolic flow.
Second, pulsed wave Doppler analysis was performed
using color flow as a guide. Spectral Doppler tracings were
recorded during the baseline condition and after adenos-
ine-induced hyperemia. The dosage rate of adenosine
(Adenoscan, Sanofi-Synthelabo, Berlin, Germany) was
0.140 mg/kg/min. CFR was calculated by dividing average
peak velocity during adenosine infusion by that at base-
line. CFR values were expressed in percent after multipli-
cation with 100 (Figure 1). A CFR below 200% was
regarded as pathologic according to previous findings [8].
Statistics
Data are presented as median values, with the minimum
and maximum values given in parentheses. The Spearman
correlation coefficient was calculated to compare continu-
ous variables. The statistical significance of differences
between groups was determined by the paired and
unpaired Wilcoxon test, respectively. A p-value of ≤ 0.05
was regarded as statistically significant.
Results
We investigated 43 diabetic males who reported erectile
dysfunction, which was confirmed by urologic measure-
ments identifying a vascular origin in 39/43 patients and
a neurogenic origin in 4/43. None of the patients had a
history of myocardial infarction or reported typical symp-
toms of angina pectoris; however, 4 patients reported dys-
pnea during effort. Systolic function of the left ventricle
was normal in all patients as determined by echocardiog-
raphy. Stress ECG did not suggest myocardial ischemia at
the 100 Watt level in any patient. However, at a higherCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/8
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work load it was positive in three asymptomatic patient in
whom heart catheterization revealed coronary artery dis-
ease with indication for coronary intervention or bypass
surgery in two. Stress ECG was inadequately negative in
11 patients who developed dyspnea during exercising. In
the presence of cardiac risk factors, coronary angiography
was advised and performed in all of those patients. Severe
coronary 2- or 3-vessel disease was found in 8 patients
necessitating coronary intervention in 2 patients, surgical
revascularization in 4 and medical therapy in 2; all of
those patients were excluded from further analysis. Insig-
nificant coronary artery sclerosis was found in the other 3
patients. In these 3 and the remaining patients, CFR meas-
urement was performed. Baseline CFR measurement
revealed a pathologic reduction of coronary flow reserve
in two patients. In both patients the study was halted.
Heart catheterization was advised and performed in both,
exhibiting a chronic total occlusion of the right coronary
artery in one, and severe coronary 2-vessel disease with
stenosis of the left main coronary artery in the other
patient. Treatment included medical therapy and bypass
surgery, respectively. Transthoracic Doppler signals were
not sufficient to allow reproducible flow measurements in
8 patients, which was mainly caused due to extreme obes-
ity. Those patients did not receive sildenafil. Adenosine
infusion was not tolerated by two patients. Patient base-
line characteristics for patients eligible to receive sildenafil
and those who were not are summarized in Table 1.
CFR measurements at baseline and after sildenafil were
performed in 21 patients. Minor side effects occurred in 5
patients including headache, flush and nasal congestion.
Blood pressure decreased significantly after sildenafil (∆
RR syst. -10 mmHg, ∆ RR diast. -8 mmHg, p < 0.002). One
Pulse wave Doppler recording of blood flow in the left anterior descending coronary artery before (a) and after (b) adenosine  infusion at baseline and corresponding recordings after sildenafil (c and d) in one patient Figure 1
Pulse wave Doppler recording of blood flow in the left anterior descending coronary artery before (a) and after (b) adenosine 
infusion at baseline and corresponding recordings after sildenafil (c and d) in one patient.
Before Sidenafil
CFR 270 %
After Sidenafil
CFR 260 %Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/8
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patient experienced vasovagal syncope 30 minutes after
ingestion of sildenafil which was treated by a rapid vol-
ume substitution. CFR measurements were repeated in
this patient at a later time and were performed without
complications. Baseline CFR values were within the lower
normal range, except in 4 patients in whom it exceeded
300%.
At baseline, CFR correlated inversely with the value of
individual HbA1c (r = 0.5, p = 0.04). The mean average
coronary flow velocities at baseline and after adenosine
were higher in obese patients and those with left ventricu-
lar hypertrophy (p < 0.001), and correlated with the body
mass index (r = 0.52, p = 0.01). Furthermore, the increase
of the mean and peak average coronary flow in response
to the administration of adenosine correlated with the
duration of the diabetes (r = 0.6, p < 0.001).
CFR after sildenafil administration decreased insignifi-
cantly in 11/21 patients (∆ CFR -10%, p = 0.3). Accord-
ingly, there was a trend for a smaller average mean flow
velocity response to adenosine after sildenafil compared
to baseline measurements (∆ average mean flow velocity -
0.06 m/s, p = 0.06). The decrease of CFR was more pro-
nounced in obese diabetics (BMI > 25 kg/m2) who had a
HbA1c > 7.0 % and left ventricular hypertrophy, while for
the other patients CFR tended to increase after sildenafil
(∆ CFR -10 % vs 1 %, p = NS). None of the patients had
the CFR drop below 200% after administration of
sildenafil.
Discussion
Erectile dysfunction caused by microvascular or neuro-
genic disturbance can be improved by sildenafil and other
phosphodiesterase type 5 inhibitors. Microvascular dys-
function is mostly caused by factors that enhance risk for
cardiovascular disease. Not surprisingly, patients with
overt cardiovascular disease exhibit a high erectile dys-
function rate [5]. In patients with symptomatic myocar-
dial ischemia, nitrates are commonly prescribed to
improve anginal status. The concomitant use of nitrates
and sildenafil causes a potentiation of vasodilating effects
inherent to both drugs [11,12]. Systemic hypotension
aggravating myocardial ischemia in the presence of signif-
icant coronary artery disease after ingestion of both drugs
is believed to be the cause for cardiac deaths [11,13,14].
Because the concomitant use of these drugs has been pro-
hibited, patients with symptomatic myocardial ischemia
can not be treated with sildenafil for erectile dysfunction.
Vascular and metabolic effects of sildenafil in the presence
of myocardial ischemia and the resulting risk potential is
unknown since patients with significant and symptomatic
heart disease have been excluded from most clinical trials
[13]. Cardiac expenditure during sexual activity varies
widely and silent myocardial ischemia does frequently
occur during sexual intercourse in patients with chronic
ischemic heart disease [15]. Myocardial ischemia
enhances ventricular ectopy and thereby can cause sudden
death. Ectopy might be enhanced due to the proarrhyth-
mogenic effects which were shown to occur at high dos-
ages of sildenafil by prolongation of cardiac
repolarization [16]. Furthermore, sildenafil increases
sympathetic activity resulting in elevated plasma nore-
pinephrine levels and sympathetic nerve traffic [17]. With
this knowledge, the effects of sildenafil on cardiac micro-
circulation are of interest, especially in diabetics who
develop endothelial dysfunction during the course of the
Table 1: Baseline Characteristics
Patients receiving sildenafil (n = 21) Patients not receiving sildenafil (n = 22) p
Age (years) 60 (50 – 69) 62 (35 – 74) NS
Body Mass Index (kg/m2) 27 (24 – 36) 28 (23 – 47) NS
Diabetes type 2 17 (81 %) 21 (96 %) NS
Duration of diabetes (years) 11 (3 – 30) 10 (2 – 39) NS
HbA1c (%) 7.3 (5.8 – 10) 8.1 (5.2 – 10.4) 0.04
Hypercholesterinemia 10 (48 %) 10 (45 %) NS
Smoker 1 (5 %) 8 (36 %) < 0.01
Hypertension 14 (67 %) 17 (77 %) NS
Family history of CAD 3 (14 %) 5 (23 %) NS
Apoplex or periph. arterio-occlusive dis. 4 (19 %) 1 (5 %) 0.04
LV hypertrophy 11 (52 %) 14 (64 %) NS
Diabetic organ dysfunction 14 (67 %) 18 (82 %) NS
Vascular ED 17 (81 %) 19 (86 %) NS
Maximum work load during stress test (W) 150 (75 – 200) 125 (100 – 200) 0.06
Max. heart rate at stress test (/min) 138 (103 – 161) 140 (109 – 166) NS
Abbreviations: CAD: coronary artery disease, LV: left ventricle, ED: erectile dysfunctionCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/8
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disease and who more frequently have silent ischemic
events.
Estimation of the coronary artery flow reserve utilizing
adenosine permits detection of clinically relevant restric-
tion of myocardial blood flow during maximum vasodil-
atation resembling hemodynamic changes during
physical exercise [8,18]. The deterioration of CFR allows
identification of severe stenoses of epicardial coronary
arteries and microvascular disturbances due to endothe-
lial dysfunction with high sensitivity. Previous investiga-
tions in diabetics demonstrated an inverse correlation
between the duration and elevation of blood sugar levels
and impairment of CFR [19,20]. Not surprisingly, patients
of this study who had suboptimally adjusted long-stand-
ing diabetes exhibited a CFR which was uniformly in the
lower normal range, indicating the presence of a microcir-
culatory disturbance. CFR measurements of the LAD in
animal studies have demonstrated an increase of the
mean flow velocity after sildenafil [21,11]. In contrast we
found a modest reduction of the CFR due to sildenafil in
half of the diabetic study patients, but in none of them did
CFR decrease below 200 %, which is known to represent
a cut-off value to indicate clinically relevant myocardial
minor perfusion during exercising [8]. However, this is in
accordance with CFR measurements performed in normal
coronary arteries in animal models with sildenafil, indi-
cating that cGMP-mediated dilatation of resistance vessels
contributes little to the shear stress-induced vasodilata-
tion augmented by adenosine [21,22]. Thus, sildenafil is
unlikely to enhance myocardial ischemia during physical
exercise in men with metabolically, severely reduced CFR.
The risk of myocardial ischemia during sexual activity
with a familiar partner is low, if the patient can achieve a
minimum of 5–6 METS on an exercise test [23]. It was
therefore recomended to perform a stress test with ≥ 5
METS in patients at risk of coronary artery disease, which
should be completed without symptoms of angina pec-
toris or myocardial ischemia [13]. A work load of 100 W
corresponds to this recommended metabolic equivalent.
No evidence of myocardial ischemia at the 100 Watt level
was observed in any patient during the stress test. We
intended to perform a diagnostic stress test in each patient
reaching the age adopted submaximal heart rate; however,
most patients were not able to reach their maximal work
load, although in 3 a positive result was obtained. Of
those, two exhibited CAD in subsequent heart catheteriza-
tion. Although not having objective signs of a coronary
artery disease, invasive diagnostics were performed
because of safety reasons in 16 patients reporting atypical
chest pain or dyspnea with the presence of 3 or more car-
diac risk factors. The surprisingly high number of patients
who were demonstrated to have severe coronary artery ste-
nosis or occlusion amounted to about 30% of all study
patients. Routine examination would probably not have
identified most of these severe CAD cases. Therefore, a
critical revision of clinical findings on an individual basis
should be made in diabetic patients. Furthermore, we
were able to detect severe CAD in 2 patients, including a
high grade stenosis of the left main coronary artery in one,
by pathologic results of the CFR measurements while clin-
ical assessment was unremarkable.
Recently, several studies investigated hemodynamic
effects of sildenafil in the presence of high grade coronary
artery stenoses. In an animal investigation sildenafil
increased poststenotic blood flow due to lowering
peripheral resistance in the presence of a flow limiting ste-
nosis of the LAD [23], whereas in another study it did not
[25]. In a human investigation, sildenafil increased CFR
values 13 percent above baseline levels in the stenosed
arteries and in undiseased reference vessels [26]. Contrary
to the former investigation in which 43% were diabetics,
CFR generally decreased in our study. The decrease of CFR
was mainly seen in the presence of left ventricular hyper-
trophy, obesity and an inadequately adjusted diabetes, a
constellation that is paralleled by severe disturbance of
endothelial function. Since CFR results also diverged in
the study of Hermann et al. [26], we speculate that more
severe microcirculatory dysfunction in diabetics with a
high risk profile is responsible for this lowered endothe-
lial responsiveness. However, reduction of the adenosine-
mediated increase of the mean flow velocity after sildena-
fil might be also a result of a more pronounced dilatation
of epicardial coronary arteries, since a modest dilatation
of coronary arteries induced by sildenafil was found in ex
vivo studies [11,27].
Individual values of CFR before and after sildenafil, including  mean values and SD Figure 2
Individual values of CFR before and after sildenafil, including 
mean values and SD.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/8
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Taking the results of these studies together, it can be
stressed that sildenafil does not induce or enhance myo-
cardial ischemia during rest or exercise in the presence of
clinically significant coronary macro- or microangiopa-
thy. However, patients with stress-induced myocardial
ischemia and erectile dysfunction, who are enabled to
resume sexual activity using sildenafil, are at risk of suffer-
ing from ischemia-induced cardiac events [14]. Therefore,
in diabetics with an elevated cardio-vascular risk profile,
intensive judgement of cardiac risk on an individual basis
should be performed before administration of sildenafil.
Limitations of the Study
The CFR was measured only in the LAD, raising the ques-
tion of representativity of measurements for the other cor-
onary arteries. However, invasive measurements have
shown that variation of individual CFR values is low
among the coronary arteries unless a severe stenosis
obstructs one of them [28].
Investigations were performed at a dosage of 50 mg silde-
nafil. Repetitive measurements with dosage escalation
were not performed since studies of hemodynamic effects
of sildenafil did not indicate clinically relevant effects
with dosages exceeding 50 mg [29,30].
The study did lack a control group and no repetitive CRF
measurements were performed. Validation of CFR meas-
urements in a larger study has shown that the intraindi-
vidual variability and the day-to-day variability are low
[10]; therefore, a statistical error is not likely to occur in
the given setting. Also intra- and interoberver variability
have been shown to be low (r = 0.95, and 0.91); in this
study all measurements were made by the person who
performed the validation studies.
Conclusions
Sildenafil does not alter coronary flow reserve in diabetic
patients with erectile dysfunction having low coronary
flow reserve at baseline. Diabetics with erectile dysfunc-
tion having two or more risk factors exhibited a high prev-
alence of severe coronary artery disease. Most of those
patients have silent ischemia that was not detected by the
recommended examination criteria. Examinations to
determine eligibility of those patients for sildenafil use
should be performed more intensively than in other
males with erectile dysfunction.
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